InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models
InSphero AG / InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support
Schlieren, Switzerland, June 13, 2018 (GLOBE NEWSWIRE) -- InSphero AG today announced that it has raised USD 10 million in its latest funding round with additional financing, secured from internal and external investors, bringing its total funding to date to USD 35 million. An innovative provider of 3D cell-based platforms for drug discovery and efficacy testing, InSphero will apply the funds to further enhance its discovery platforms for metabolic diseases and cancer.
InSphero's comprehensive solutions for preclinical drug safety and efficacy testing are based on 3D microtissues, which are phenotypic models of the smallest functional unit of a tissue or organ. These drug-discovery and testing platforms combine scalable 3D technology, ISO quality-controlled 3D human tissue models, 3D-optimized media, as well as tailored assay services and support. Drug-discovery partners immediately gain access to the depth and breadth of InSphero's experience in developing and applying 3D models for liver toxicology, metabolic diseases (e.g, T1 and T2 diabetes, and liver diseases NAFLD and NASH), and oncology.
A new milestone for the market leader is the successful linking of different 3D microtissues through a unique microfluidic organ-on-a-chip technology that enables researchers to better understand how drugs affect the human body as a whole. The technology is used in ongoing research collaborations with academic and industry partners, such as Roche Pharmaceuticals in Basel, Switzerland, and the Swiss Federal Institute of Technology (ETH). The technology, baptized Akura(TM) Flow, promises to transform drug discovery and development, with the potential to make animal testing in pharma and cosmetic companies obsolete.
InSphero CEO and co-founder Dr. Jan Lichtenberg says, "This funding will enable us to complete our transition from a supplier to a partner, offering our customers the full value of our 3D technology and knowledge of applied 3D disease modeling-whether they need a complex custom model, a body-on-a-chip system, or an experienced collaborator for a long-term, joint discovery project."
Former GM of Promega Switzerland Dr. Jürg Gysi, who is now President of the InSphero Board of Directors and an investor in this round, adds, "Over the past several years, InSphero has created tangible benefits for pharma and biotech companies worldwide. This secured funding will support the company's continuing growth, which was exceeding 40% in the second half of 2017 alone."
InSphero has received ongoing fundraising support from Venturelab, which has nurtured their evolution from a Swiss start-up to a global biotechnology leader, with customers from all top ten pharmaceutical companies.
For more information about InSphero, visit www.insphero.com.
Dr. Frank Junker
Chief Business Officer
Phone +41 44 5150490
Dr. Jan Lichtenberg
Chief Executive Officer
Phone +41 44 5150490
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight(TM) Platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g, T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). 3D InSight(TM) Discovery and Safety Platforms are used by all top 10 pharmaceutical companies and are available in 96-well, 384-well, and organ-on-a-chip formats to drive efficient innovation throughout all phases of drug development.
Karen Dowell InSphero AG 800-779-7558 email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InSphero AG via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
CORRECTING and REPLACING -- PRESS ALERT & INVITATION: Arbitrade to Hold a Press Conference on June 28th From Bermuda - Its New Global Headquarters23.6.2018 14:00 | Pressmeddelande
NEW YORK, June 23, 2018 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by Arbitrade, please note that the correct date of the event is Thursday, June 28, 2018 at 8:00 a.m. EDT. The corrected release follows: This is an invitation to all media following Arbitrade and/or covering the cryptocurrency markets. You are invited to join Arbitrade's Chairman, Len Schutzman, and management who will discuss their progress toward establishing Arbitrade as a world-class cryptocurrency exchange and coin company. They will also discuss their move and incorporation into Bermuda, one of the world's best regulated jurisdictions and a platform from which Arbitrade will reach out to several international markets. It will be a lively discussion that will also include details of the many economic and social advantages and new jobs that companies, like Arbitrade, will bring to countries in which they settle and do business around the world. Details of how to access the pr
15th Consecutive Nasdaq Closing Cross Sets Record for Number of Shares Traded During 2018 Russell US Indexes Reconstitution22.6.2018 23:19 | Pressmeddelande
NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the Nasdaq Closing Cross had a record day as it was used for the 15th consecutive year to rebalance Nasdaq-listed securities in the entire family of Russell U.S. Indexes, part of leading global index provider FTSE Russell, during their annual reconstitution. A record 1.188 billion shares representing $39.26 billion were executed in the Closing Cross in 0.935 seconds across some 2,591 Nasdaq-listed stocks. This compares to 2017, when Nasdaq executed 972 million shares representing $28.9 billion executed in 0.861 seconds across 2,499 Nasdaq-listed stocks. "Today, we saw a record-breaking performance for the Nasdaq Closing Cross, which benefits issuers and investors alike with transparent and efficient price discovery," said Tom Wittman, Head of Global Equities and Executive Vice President of Global Trading and Market Services at Nasdaq. "The rebalance is an important event to ensure that the Russell U.S. ind
PRESS ALERT & INVITATION: Arbitrade to Hold a Press Conference on June 28th From Bermuda - Its New Global Headquarters22.6.2018 22:29 | Pressmeddelande
NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- This is an invitation to all media following Arbitrade and/or covering the cryptocurrency markets. You are invited to join Arbitrade's Chairman, Len Schutzman, and management who will discuss their progress toward establishing Arbitrade as a world-class cryptocurrency exchange and coin company. They will also discuss their move and incorporation into Bermuda, one of the world's best regulated jurisdictions and a platform from which Arbitrade will reach out to several international markets. It will be a lively discussion that will also include details of the many economic and social advantages and new jobs that companies, like Arbitrade, will bring to countries in which they settle and do business around the world. Details of how to access the press briefing webcast are as follows: Please register now for the upcoming Arbitrade Conference Call: Date: Wednesday, June 27, 2018 Time: 8:00 a.m. EST We recommend that you connect to the meeting at l
Northland Power's Hai Long Offshore Wind Project Awarded Additional 744 Megawatts in Taiwan Auction22.6.2018 14:15 | Pressmeddelande
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that the Taiwan Bureau of Energy ("BOE") has awarded 232 megawatts ("MW") to the Hai Long 2 offshore wind farm ("Hai Long 2") and 512 MW to the Hai Long 3 offshore wind farm ("Hai Long 3") under Taiwan's offshore wind auction program. These awards are separate from and in addition to the 300 MW in 2024 that Hai Long 2 was allocated by the Taiwan BOE on April 30, 2018 under Taiwan's Feed-in-Tariff ("FIT") program. Northland and its partner Yushan Energy Co. Ltd. ("Yushan Energy") own 60% and 40%, respectively, of Hai Long 2 and Hai Long 3. This is another significant step for Northland in Taiwan, with a second and third project progressing to connect to Taiwan's grid in 2025, subject to securing 20-year power purchase agreements. Taken together with the FIT award, the Hai Long 2 and Hai Long 3 offshore wind farms now total 1,044 MW of offshore wind capacity in Taiwan. Northland is bui
Williams Scotsman to Acquire ModSpace22.6.2018 13:09 | Pressmeddelande
Creates an industry-leading specialty rental services provider with over $1 billion of combined revenue and over 160,000 rental units across North America Leverages, and further strengthens, Williams Scotsman's scalable operating platform to capture an estimated $60 million of cost synergies Combines the best of both companies' go-to-market strategies, benefiting our customers and accelerating the expansion of Williams Scotsman's turnkey "Ready To Work" solutions across a broader asset base and enhanced branch network Total enterprise value of approximately $1.1 billion represents 6.6x ModSpace's Adjusted EBITDA for the twelve month period ended March 31, 2018, inclusive of forecast cost synergies and the expected value of acquired tax attributes1 ,2 BALTIMORE, June 22, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman") the leading specialty rental services provider of innovative modular space and portable storage solutions across North America, today anno
GMAC Launches 'Study in China' Initiative in Partnership with 11 Leading Business Schools in China22.6.2018 06:01 | Pressmeddelande
BEIJING and HONG KONG, June 22, 2018 (GLOBE NEWSWIRE) -- On June 22, the Graduate Management Admission Council (GMAC) joins hands with 11 leading business schools in China to launch the "Study in China" initiative. This partnership marks the opening of an interactive platform for international students across 20 Belt and Road (B&R) regions to explore opportunities in China and to pursue higher education in business-related fields. The "Study in China" initiative aims to meet rapidly growing international student demand and to champion China as a world-class study destination and emerging global hub for business education. The "Study in China" online portal (www.studyinchinamba.com) officially launched today allows students to discover more about studying and living in China. The newly designed English-language website connects prospective students with partner business schools and offers access to an abundance of information to help find the perfect fit for their China education experi
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum